When a Uniquely Effective Drug is Teratogenic: The Case of Isotretinoin

Andrew Holmes, Sidney Wolfe, Gerald Faich, Franz Rosa, Robert S. Stern, Allen A. Mitchell

Research output: Contribution to journalLetter

Abstract

To the Editor: Just one week after a Journal editorial on the disclosure of investigators' financial ties (April 6 issue),1 there was a Sounding Board article on isotretinoin (Accutane) by Dr. Robert Stern (April 13 issue),2 in which no disclosure was made of his substantial association with Hoffmann–LaRoche (Roche), the manufacturer of isotretinoin. At the April 26, 1988, meeting of the Dermatologic Drugs Advisory Committee of the Food and Drug Administration, Dr. Stern disqualified himself from voting on Accutane because of what he described as “my continuing support for a research project from Hoffmann–LaRoche company and other consulting work I…

Original languageEnglish (US)
Pages (from-to)756-758
Number of pages3
JournalNew England Journal of Medicine
Volume321
Issue number11
DOIs
StatePublished - Sep 14 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'When a Uniquely Effective Drug is Teratogenic: The Case of Isotretinoin'. Together they form a unique fingerprint.

  • Cite this

    Holmes, A., Wolfe, S., Faich, G., Rosa, F., Stern, R. S., & Mitchell, A. A. (1989). When a Uniquely Effective Drug is Teratogenic: The Case of Isotretinoin. New England Journal of Medicine, 321(11), 756-758. https://doi.org/10.1056/NEJM198909143211110